Navigation Links
Ontario Cancer Institute, US scientists discover compound that kills lymphoma cells
Date:4/12/2010

An international research team co-led by the Ontario Cancer Institute (OCI) has discovered a compound that kills specific lymphoma cells a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.

The research findings, published online today in Cancer Cell (DOI 0.1016/j.ccr.2009.12.050), show how the scientists used a chemical compound to block protein BCL6, the cancer-causing culprit in about half of all non-Hodgkins lymphoma cases, the fifth most common type of cancer in Canadians.

Co-principal investigator Dr. Gilbert Priv, an OCI senior scientist who specializes in analyzing the structure and function of cancer-related proteins, says: "We have identified a new avenue for drug development. It is exciting because until now, the prevailing wisdom has been that cancer proteins such as BCL6 would not respond in this way to chemical manipulation. We have proven otherwise."

The scientists began their quest using three-dimensional crystallography and computer-aided drug design to filter over one million potential compounds to about 100 that merited further research. They continued narrowing the field, down to 10 and, eventually, to the one compound that proved successful. In lab experiments, there was even better news not only did the compound kill lymphoma cells, it was also non-toxic.

Dr. Priv explains further: "If you picture cell proteins as a circuit board, we have found a way to short-circuit a defective connection without destroying the entire board. This is the potential of targeted therapy to kill specific cancer cells and leave healthy cells untouched."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1

Related biology news :

1. Cancer drug effectiveness substantially advanced
2. Disparities persist in outcomes for African-American women with advanced breast cancer
3. The immune systems guard against cancer
4. Chip checks for oral cancer
5. New discovery is a significant boost to cancer research
6. VARI study could improve treatments for prostate cancer
7. New cancer therapy may fight cardiovascular disease
8. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
9. Advances reported in quest for drugs targeting childhood cancer
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. ... developer of innovative sensor-based diagnostic products, today announced the closing ... new and existing investors.  Proceeds from the financing will be ... , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The device,s ...
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
(Date:1/7/2016)... , Jan. 7, 2016  A United States ... the first court in the country to interpret a ... lawsuit to go forward against the photo website Shutterfly ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and ... plaintiff alleges that Shutterfly violates the Illinois Biometric Privacy ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
Breaking Biology Technology: